Veracyte Stock Price, News & Analysis

Veracyte (NASDAQ:VCYT) announced groundbreaking results from the BALANCE trial, validating that their PAM50 molecular biomarker can predict hormone therapy effectiveness in recurrent prostate cancer patients. The study, presented at ASTRO 2025, demonstrated that among 127 patients with luminal B tumors, 72% taking apalutamide with salvage radiation therapy avoided biochemical failure, compared to 54% in the placebo group.

The prospective validation trial involved 295 men with non-metastatic prostate cancer following prostate removal surgery. The PAM50 biomarker, available through Veracyte's Decipher GRID platform, represents the first predictive biomarker validated in a prospective, randomized trial for non-metastatic prostate cancer, marking a significant advancement in personalized treatment approaches.

This breakthrough enables more precise selection of patients who would benefit from hormone therapy, potentially helping others avoid unnecessary treatment and side effects. The study results are part of 9 Decipher-focused abstracts being presented at the conference.

Veracyte (NASDAQ:VCYT) announced that groundbreaking data validating a molecular signature for predicting hormone therapy effectiveness in recurrent prostate cancer patients will be presented at ASTRO 2025. The research, conducted using Veracyte's Decipher GRID tool, is part of nine Decipher-focused abstracts to be presented at the conference.

The presentations include a significant double-blinded placebo-controlled biomarker trial of Apalutamide and radiotherapy, along with an analysis of adverse molecular features across over 200,000 patients. The conference will be held from September 27 to October 1 at the Moscone Center in San Francisco.

Veracyte (NASDAQ:VCYT) announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting in Scottsdale, Arizona from September 10-14. The research presentations leverage the company's Afirma Genomic Resource for Intelligent Discovery (GRID), which represents the world's largest molecular database for thyroid nodules.

The presentations include studies on cell-surface targets in thyroid tumors, mRNA expression signatures for predicting histopathology, molecular profiling comparisons between Black and White patients, and genomic landscape analysis of thyroid nodules in elderly patients. These studies stem from Veracyte's extensive database of thyroid-nodule whole-transcriptome-derived genomic profiles, which the company makes available to eligible researchers.

Veracyte (NASDAQ:VCYT) announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on September 9, 2025, at 4:50 p.m. Eastern Time. Investors can access a live audio webcast of the presentation through Veracyte's investor relations website, with the replay remaining available for 90 days following the event.

Veracyte (NASDAQ:VCYT) announced groundbreaking results from the Phase 3 STAMPEDE trial, published in Cell, demonstrating that their Decipher Prostate Genomic Classifier can predict chemotherapy effectiveness in metastatic prostate cancer patients.

The study of 1,523 patients revealed that those with higher Decipher scores showed improved survival benefit from docetaxel treatment (HR 0.64), while those with lower scores did not benefit significantly (HR 0.96). The trial followed patients for a median of 14 years.

Veracyte launched the expanded Decipher test for metastatic prostate cancer in June 2025, addressing an urgent need as prostate cancer causes nearly 400,000 deaths globally and is the second-leading cause of cancer deaths among U.S. men, with 315,000 new diagnoses expected this year.

Veracyte (NASDAQ:VCYT) has completed enrollment for its NIGHTINGALE clinical utility trial, evaluating the Percepta Nasal Swab test for lung cancer detection. The trial has successfully enrolled 2,400 patients across 90+ centers in the United States.

The prospective, randomized, blinded trial will follow patients for up to two years to assess the test's ability to reduce unnecessary procedures for benign nodules and accelerate treatment for cancerous ones. The Percepta Nasal Swab test has demonstrated strong clinical validation results, showing 97% sensitivity with 40% specificity for low-risk nodules and 92% specificity with 57% sensitivity for high-risk nodules.

Veracyte (NASDAQ:VCYT) reported strong Q2 2025 financial results with total revenue growing 14% year-over-year to $130.2 million. Testing revenue increased 14% to $122.3 million, driven by exceptional performance of Decipher tests, which achieved a 28% volume growth. The company recorded a GAAP net loss of $1.0 million, including $20.5 million in one-time impairment charges related to French subsidiary restructuring.

Key highlights include Decipher revenue growth of 24% to $76.3 million and Afirma revenue increase of 5% to $43.4 million. The company generated $33.6 million in operating cash flow and ended the quarter with $320.7 million in cash and equivalents. Following strong performance, Veracyte raised its full-year 2025 testing revenue guidance to $477-483 million and adjusted EBITDA margin guidance to 23.5%.

Veracyte (NASD: VCYT) is set to join the S&P SmallCap 600 index effective prior to market opening on July 29, 2025. The company will replace Triumph Group (NYSE: TGI), which is being acquired by Warburg Pincus LLC and Berkshire Partners LLC.

The index change comes as Triumph Group's acquisition is expected to close soon, pending final conditions. Veracyte will be added to the Health Care sector of the index, while Triumph Group will be removed from the Industrials sector.

Veracyte (NASDAQ:VCYT), a cancer diagnostics company, has scheduled its second quarter 2025 financial results release for August 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.

Investors can access the live webcast through the company's website, and a replay will be available at the investor relations section. Conference call participation requires pre-registration through the provided link.